IP Library Patent Application 18553882
Patent Application
App. No. 18/553,882

A COMPOSITION FOR PROMOTING GLP-1 SECRETION

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/553,882
Abstract

An object of the present invention is to provide a composition having an effective GLP-1 secretion-promoting effect. The present invention attains this object by providing a composition for promoting GLP-1 secretion, comprising component (A) and component (B) as active ingredients, wherein said component (A) is a glycosyl naringenin and said component (B) is one or more selected from a group consisting of α-pinene, β-pinene, sabinene, camphene, valencene, β-caryophyllene, β-ionone, methyl anthranilate, methyl N-methylanthranilate, thymol, and nootkatone.

Claims (17)

1 . A composition for promoting GLP-1 secretion, comprising component (A) and component (B) as active ingredients, wherein said component (A) is a glycosyl naringenin and said component (B) is one or more selected from a group consisting of α-pinene, β-pinene, sabinene, camphene, valencene, β-caryophyllene, β-ionone, methyl anthranilate, methyl N-methylanthranilate, thymol, and nootkatone.

2 . The composition for promoting GLP-1 secretion according to claim 1 , wherein said component (A) is 3″-α-monoglucosyl naringin.

3 . The composition for promoting GLP-1 secretion according to claim 1 , wherein said component (B) is thymol and/or nootkatone.

4 . The composition for promoting GLP-1 secretion according to claim 1 , comprising said component (A) and said component (B) at a molar ratio of 10,000:1 to 1:10.

5 . The composition for promoting GLP-1 secretion according to claim 1 , comprising said component (A) in an amount of 0.0001% by mass or more.

6 . The composition for promoting GLP-1 secretion according to claim 1 , which is for use in at least one of the followings: prevention or improvement of obesity, diabetes, and postprandial hyperglycemia; suppression of elevation of blood glucose level; inhibition of glucagon secretion; inhibition of gastric excretion and gastric acid secretion; suppression of appetite; suppression of food intake; and induction of satiety.

7 . A composition, comprising component (A) and component (B), wherein said component (A) is a glycosyl naringenin and said component (B) is one or more selected from a group consisting of α-pinene, β-pinene, sabinene, camphene, valencene, β-caryophyllene, β-ionone, methyl anthranilate, methyl N-methylanthranilate, thymol, and nootkatone.

8 . The composition according to claim 7 , comprising said component (A) and said component (B) at a molar ratio of 10,000:1 to 1:10.

9 . The composition according to claim 7 , wherein said component (A) is 3″-α-monoglucosyl naringin.

10 . The composition according to claim 7 , wherein said component (B) is thymol and/or nootkatone.

11 . The composition according to claim 7 , comprising said component (A) in an amount of 0.0001% by mass or more.

12 . A food or beverage, comprising the composition according to claim 1 .

13 . A supplement, comprising the composition according to claim 1 .

14 . A flavoring agent, comprising the composition according to claim 1 .

15 . A pharmaceutical or quasi-drug, comprising the composition according to claim 1 .

16 . A feed, comprising the composition according to claim 1 .

17 - 21 . (canceled)

Assignments (2)
NUNC PRO TUNC ASSIGNMENT Recorded Sep 26, 2025
From: TAKAHASHI, JUN; YAMADA, MIKA; ARAI, NORIE; HASHINI, EMIKO; MITSUZUMI, HITOSHI
To: HAYASHIBARA CO., LTD.
Reel/Frame 072389/0128 →
CHANGE OF NAME Recorded Nov 18, 2024
From: HAYASHIBARA CO., LTD
To: NAGASE VIITA CO., LTD.
Reel/Frame 069379/0708 →